Freedom Broker initiates coverage on Arcturus Therapeutics with Buy rating
Freedom Broker analyst Ilya Zubkov has initiated coverage on Arcturus Therapeutics with a Buy rating and announced a price target of $27.
*this image is generated using AI for illustrative purposes only.
Freedom Broker analyst Ilya Zubkov has initiated coverage on Arcturus Therapeutics with a Buy rating and announced a price target of $27. This rating suggests a positive outlook for the company's stock performance.
Coverage Details
The initiation of coverage provides a new investment perspective on Arcturus Therapeutics. The price target set by the analyst indicates the expected valuation level for the shares.
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $27 |
| Analyst | Ilya Zubkov |
What specific catalysts does Freedom Broker anticipate will drive Arcturus Therapeutics to the $27 price target?
How might this new coverage influence other analysts' ratings on Arcturus Therapeutics in the near term?
What upcoming clinical trial readouts or regulatory milestones could validate the Buy rating?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
